

Genomic Medicine

PhD block course for the PhD Program Molecular and Translational Biomedicine
November 27 – December 1 2017 in Zurich

Student Exercise 4

Siu, L.L., Ivy, S.P., Dixon, E.L., Gravell, A.E., Reeves, S.A. and Rosner, G.L. 2017. Challenges and opportunities in adapting clinical trial design for immunotherapies. *Clinical Cancer Research* 23(17), pp. 4950–4958.

DOI: [10.1158/1078-0432.CCR-16-3079](https://doi.org/10.1158/1078-0432.CCR-16-3079)

Assignment:

1. Read the paper and discuss it in your group.
2. Prepare a 10 min presentation of the paper, pay special attention to the section on seamless phase I-II trial designs.
3. How could such a clinical trial be implemented in Zurich?
 - a. Make sure that everyone understands what a checkpoint inhibitor is and knows the difference between CTLA-4, PD-1, and PD-L1!
 - b. Walk the audience through the checklist for an immunotherapy trial – try to weave in a concrete example.
 - c. What could be the major non-methodological challenges implementing the trial in Switzerland, and how could these be addressed?

After your presentation, there will be a discussion of 10-15 min.

Note: All time limits are sharp – we will interrupt you.